Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127533641 | 12753364 | 1 | I | 20160206 | 20160916 | 20160916 | PER | BE-LUPIN PHARMACEUTICALS INC.-2016-00699 | LUPIN | SCHRIJVERS R, TUYLS S, BREYNAERT C. SUBGROUPS IN CEPHALOSPORIN ALLERGY, MAKING A PATIENT-TAILORED APPROACH REDUNDANT?. J-ALLERGY-CLIN-IMMUNOL. 2016;137(1):331. | 74.00 | YR | F | Y | 0.00000 | 20160914 | MD | BE | BE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127533641 | 12753364 | 1 | PS | CEFUROXIME. | CEFUROXIME | 1 | Oral | UNKNOWN | 65135 | ||||||||||
| 127533641 | 12753364 | 2 | SS | CEFUROXIME. | CEFUROXIME | 1 | UNKNOWN | 65135 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127533641 | 12753364 | 1 | Urinary tract infection |
| 127533641 | 12753364 | 2 | Respiratory tract infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127533641 | 12753364 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127533641 | 12753364 | Anaphylactic reaction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |